Karyopharm Therapeutics Inc.
Moat Score — Karyopharm Therapeutics Inc.
Total Moat Score
11 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 4 / 5 | Karyopharm pioneered selective inhibition of nuclear export and holds the patents behind XPOVIO, the first-ever approved XPO1 inhibitor, giving it a genuine first-mover IP position in a mechanism now being copied by Menarini/Stemline and Shanghai Junshi. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | As a specialty oncology company with a $1.6B accumulated deficit and ongoing going-concern risk, Karyopharm has no cost advantage; its spending on R&D and commercialization outpaces its still-modest product revenue. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 3 / 5 | As a specialty oncology drug with accelerated-approval indications and no identical substitute mechanism, XPOVIO commands premium specialty-pharma pricing, though payer pressure and the need for combination therapy in label expansions constrain this somewhat. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | There is no network effect in selling an oncology drug - prescribing decisions are driven by clinical data and payer coverage, not by other users or partners making the product more valuable. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | Oncologists can and do switch patients between lines of therapy as new data emerges; XPOVIO must continually earn its place in a treatment sequence against JAK inhibitors, IMiDs, and emerging XPO1 rivals rather than benefiting from lock-in. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 2 / 5 | Myeloma, lymphoma, and myelofibrosis markets are large enough to support multiple approved mechanisms simultaneously, so Karyopharm's scale is real but not exclusionary - competitors can and do enter alongside it. |